Improvement of cardiac function by placenta-derived mesenchymal stem cells does not require permanent engraftment and is independent of the insulin signaling pathway

Clonogenic assay Stem Cell Therapy Cell therapy
DOI: 10.1186/scrt490 Publication Date: 2014-08-21T13:02:05Z
ABSTRACT
Abstract Introduction The objective of this work was to evaluate the efficacy placenta-derived mesenchymal stem cell (MSC) therapy in a mouse model myocardial infarction (MI). Since MSCs can be obtained from two different regions human term placenta (chorionic plate or villi), cells both these were compared so that best candidate for could selected. Methods For vitro studies, chorionic (cp-MSCs) and villi (cv-MSCs) extensively characterized their genetic stability, clonogenic differentiation potential, gene expression, immunophenotype. vivo C57Bl/6 mice submitted MI and, after 21 days, received weekly intramyocardial injections cp-MSCs 3 weeks. Cells also stably transduced with viral construct expressing luciferase, under control murine virus (MSCV) promoter, used bioluminescence assay. expression genes associated insulin signaling pathway analyzed cardiac tissue placebo groups. Results Morphology, differentiation, immunophenotype, proliferation quite similar between cells. However, had greater potential higher related cycle progression genome stability. Therefore, we considered preferable isolation MSCs. Sixty days MI, cell-treated significant increase ejection fraction reduction end-systolic volume. This improvement not caused by infarct size. In addition, tracking luciferase revealed remained heart 4 first injection but survival period reduced second third injections. Quantitative reverse transcription-polymerase chain reaction involved when comparing Conclusions Improvement function did require permanent engraftment mediated pathway.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (68)
CITATIONS (27)